GlassScriptPhysician profile
Charles G Morgan, JR.
NPI 1477541696
$3,342.68
in general payments reported to CMS, 2019-2025
27 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $123 · 2021: $171 · 2022: $594 · 2023: $954 · 2024: $751 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015 · Education: $86.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.34 |
| Education | $86.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $501.64 | 2022-2024 | |
| Abbvie INC. | $340.97 | 2021-2025 | |
| Novo Nordisk INC | $292.35 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $257.10 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $242.55 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $219.26 | 2023-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $198.12 | 2021-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $197.71 | 2019-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $152.71 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.56 | 2019-2024 | Jardiance, Tradjenta |
| Esperion Therapeutics, INC. | $140.86 | 2021-2023 | Nexletol |
| Pfizer INC. | $121.32 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.40 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $81.44 | 2019-2022 | |
| Axsome Therapeutics, INC. | $56.11 | 2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $44.86 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $41.16 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $37.35 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.95 | 2019-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $28.69 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $23.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.65 | 2020 | |
| Shield Therapeutics INC | $16.58 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.12 | 2023 | Livalo, Seglentis |
| Insmed, INC. | $16.00 | 2019 | |
| Janssen Biotech, INC. | $14.17 | 2020 | |
| Allergan, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.